Association of HDL cholesterol and triglycerides with mortality in patients with heart failure by FREITAS, H.F.G. et al.
420
Braz J Med Biol Res 42(5) 2009
 H.F.G. Freitas et al.
www.bjournal.com.br
Brazilian Journal of Medical and Biological Research (2009) 42: 420-425
ISSN 0100-879X
Association of HDL cholesterol and
triglycerides with mortality in patients
with heart failure
H.F.G. Freitas, E.A. Barbosa, F.H.F.P. Rosa, A.C.P. Lima and A.J. Mansur
Instituto do Coração, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
Correspondence to: H.F.G. Freitas, InCor, FM, USP, Av. Dr. Eneas C. Aguiar, 44, 05403-900 São Paulo,
SP, Brasil
Fax: +55-11-3082-2354. E-mail: dclfreitas@incor.usp.br
It has been demonstrated that there is an association between serum lipoproteins and survival rate in patients with ischemic
cardiomyopathy, as well as in patients with non-ischemic causes of heart failure. We tested the hypothesis of an association
between serum lipoprotein levels and prognosis in a cohort of outpatients with heart failure, including Chagas’ heart disease. The
lipid profile of 833 outpatients with heart failure in functional classes III and IV of the New York Heart Association, with a mean
age of 46.9 ± 10.6 years, 655 (78.6%) men and 178 (21.4%) women, was studied from April 1991 to June 2003. The survival rate
was estimated by the Kaplan-Meyer’s method and the Cox proportional hazards models. Etiology of heart failure was ischemic
cardiomyopathy in 171 (21%) patients, Chagas’ heart disease in 144 (17%), hypertensive cardiomyopathy in 136 (16%), and
other etiologies in 83 (10%). In 299 (36%) patients, heart failure was ascribed to idiopathic dilated cardiomyopathy. Variables
significantly associated with mortality were age (hazard ratio, HR = 1.02; 95%CI = 1.01-1.03; P = 0.0074), male gender (HR =
1.77; 95%CI = 1.2-2.62; P = 0.004), idiopathic dilated cardiomyopathy (HR = 1.81; 95%CI = 1.16-2.82; P = 0.0085), serum
triglycerides (HR = 0.97; 95%CI = 0.96-0.98; P < 0.0001), and HDL cholesterol (HR = 0.99; 95%CI = 0.99-1.0; P = 0.0280).
Therefore, higher serum HDL cholesterol and higher serum triglycerides were associated with lower mortality in this cohort of
outpatients with heart failure.
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Introduction
Serum lipid and lipoprotein abnormalities have been
reported in patients with heart failure (1-5). Low serum total
cholesterol is associated with increased mortality in pa-
tients with systolic heart failure (6,7). A trend towards a
significant relationship between higher serum lipoprotein
levels and higher survival rate was suggested (3), but not
confirmed (4). Specifically, HDL cholesterol was suggested
to have antioxidant, anti-inflammatory and antithrombotic
properties that would counteract pro-inflammatory activity
in patients with heart failure (8-10).
We measured serum cholesterol, HDL cholesterol,
LDL cholesterol, and triglycerides in a cohort of outpatients
with heart failure of different etiologies, including Chagas’
heart disease, followed from 1991 to 2003. This study was
designed to test the hypothesis of an association between
serum lipid protein profile and prognosis during a long-
term follow-up and if high levels of HDL cholesterol and
triglycerides can be protective in these patients.
Patients and Methods
Patients
We studied the lipid profile of 833 outpatients with heart
failure referred for evaluation and ambulatory treatment of
heart failure to the outpatient clinic of a tertiary care refer-
ence university public hospital, selected among 1400 re-
ferred patients (mean ± SD left ventricle ejection fraction
on echocardiography 33.4 ± 4.6%; mean left ventricle
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ejection fraction on radioisotopic ventriculography 22.3 ±
8.1%) in order to identify potential candidates for heart
transplantation.
Inclusion criteria were patients under 75 years of age
with a diagnosis of functional class III or IV (NYHA) heart
failure due to systolic dysfunction. Exclusion criteria were
patients with hypertrophic cardiomyopathy, chronic ob-
structive pulmonary disease, recent myocardial infarction,
and unstable angina. In addition, patients with severe
renal or hepatic dysfunction, severe peripheral arterial
disease, cerebrovascular disease, insulin-dependent dia-
betes mellitus with end-organ damage, active infection,
coexisting neoplasm, and active peptic ulcer disease were
also excluded, as were patients with severe co-morbidities
that would make them ineligible for surgery or heart trans-
plantation (11).
Definitions
Diagnosis of heart failure was made according to the
Framingham criteria (12). Diagnosis of the etiology of
cardiomyopathy followed previously published criteria (13,
14). Chagas’ heart disease was defined as patients with
heart failure due to left ventricular systolic dysfunction and
positive serologic tests. The association of etiologies such
as ischemic and hypertensive cardiomyopathy was con-
sidered to be ischemic cardiomyopathy.
Clinical assessment protocol. Patients were referred to
the outpatient clinic after diagnosis and stabilization of
heart failure. After clinical evaluation, serum cholesterol
was evaluated in 833 (59.5%) patients, HDL cholesterol in
722 (51.5%), LDL cholesterol in 720 (51.4%), VLDL cho-
lesterol in 720 (51.4%), and serum triglycerides in 828
(59.1%).
Medical treatment was further optimized with medical
advice regarding everyday living and drug therapy, includ-
ing captopril and enalapril, furosemide and digoxin avail-
able at the Hospital Outpatient Clinic pharmacy. Carvedilol
was progressively introduced after 1998. Statin therapy
was not routinely administered.
Follow-up
Follow-up was assessed on the occasion of the last
outpatient medical visit or by telephone contact. Patients
with missed appointments at the outpatient clinic were
actively contacted by means of telephone calls. In addi-
tion, the mortality database of the São Paulo City Authority
was also scrutinized to determine patient deaths (ProAim -
Programa de Aprimoramento de Informações de Mortali-
dade do Município de São Paulo). During the 10-year
follow-up period of the study, 80 patients (7%) underwent
the first clinical evaluation and eventually were lost to
follow-up.
For the purpose of this study, death was considered to
be an event, and heart transplantation and other surgical
interventions were defined as censored observations.
Statistical analysis
After exploratory analysis to identify variables associ-
ated with mortality, survival was estimated for each demo-
graphic, clinical and laboratory variable in order to identify
variables significantly associated with the probability of
survival. Unadjusted Kaplan-Meier curves were constructed
(15) and survival probabilities were compared using log-
rank and Breslow methods. For continuous variables, pa-
tients were divided into three balanced groups according
to the terciles of distribution in order to avoid pre-estab-
lished categorizations. In the next step, Cox proportional
hazards models (16) were fitted to each variable.
The estimated hazard ratios (HR) were then obtained.
Because of missing values, the sample considered was
not the same for all models. The results are presented as
number of cases, events and censored data, P values, HR
and 95% confidence intervals (95%CI).
Ethics. The protocol was approved by the Institution
Ethics Committee. Written informed consent was obtained
from the patients after identification of potential candidates
for heart transplantation.
Results
The etiology of heart failure was ischemic cardiomyop-
athy in 171 (20.5%) patients, Chagas’ heart disease in 144
(17.3%), hypertensive cardiomyopathy in 136 (16.3%),
and other etiologies in 83 (9.9%). In 299 (35.8%) patients,
heart failure was ascribed to idiopathic dilated cardiomy-
opathy. Mean patient age was 46.9 ± 10.6 years; 655
(78.6%) were men and 178 (21.4%) were women. Ten
patients were younger than 20 years, 58 were 20 to 30
years old, 140 were 30 to 40 years old, 295 were 40 to 50
years old, 69 were 60 to 70 years old, and 3 were 70 to 71
years old.
The mean (± SD) duration of symptoms before entry in
the study was 49.1 ± 48.3 months, the mean duration of
follow-up was 658.8 days (median 462, SD = 654.8, range
3-3584) for patients who died and 1202.8 days (median
1043.5, SD = 959.3, range 1-4801) for patients who sur-
vived the last contact.
Baseline characteristics relative to the etiologies of
heart failure are shown in Table 1. Statistically significant
differences were observed in relation to duration of the
symptoms, age, heart rate, creatinine, body mass index,
gender, serum glucose, and death. In the ischemic cardio-
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Table 1. Clinical characteristics of the patients relative to the etiology of heart failure.
Variable Chagas’ disease Idiopathic Hypertensive Ischemic Other P
(N = 144) (N = 299) (N = 136) (N = 171) (N = 83)
N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD N Mean ± SD
Duration of symptoms 106 1486±1277 228 1703±1666** 95 1238±1161* 131 1183±1174* 67 1567±1642 0.0081
(days)
Age (years) 144 46.2±10.5 299 45.9±10.5 136 47.7±0.1 171 49.6±10.2 83 45.2±11.4 0.0021
Gender
Male 114 232 97 147 65 0.0402
Female 30 67 39 24 18
Deaths 51 (35.4%) 114 (38.1%) 32 (23.5%) 67 (39.2%) 27 (32.5%) 0.0312
Body mass index 63 23.2±3.5 163 24.7±4.4 83 25.2±4.4 106 25.9±4.7 36 23.8±5.0 0.0021
(kg/m2)
Systolic blood pressure 47 123.6±23.0 79 114.8±21.4 36 114.2±20.0 47 115.6±19.8 26 114.8±16.7 0.1551
(mmHg)
Diastolic blood pressure 47 85.3±20.3 79 78.2±16.8 36 82.1±16.5 48 75.0±21.1 26 76.4±15.9 0.0541
(mmHg)
Heart rate (bpm) 55 79.2±13.9 126 82.5±15.9 35 85.5±4.4 61 79.9±13.9 30 89.6±13.8 0.0071
Serum sodium (mmol/L) 140 138.7±3.6 286 138.7±3.7 130 139.2±3.5 160 139.0±3.5 79 138.9±3.1 0.6791
Hemoglobin (g/dL) 141 14.5±1.6 287 14.5±1.8 135 14.6±1.9 168 14.6±1.6 80 14.8±1.5 0.7051
Hematocrit (%) 141 43.6±4.8 287 44.2±5.7 135 44±5.9 168 44.3±4.8 80 44.4±4.7 0.7561
Leukocyte count per mm3 125 7617±2142 252 8048±2635 116 7699±2205 144 8230±2708 71 7831±2054 0.2051
Platelets ( x 1000/mm3) 110 226.0±68.3 221 226.8±74.2 104 218.0±61.7 122 215.9±69.7 60 209±59.6 0.3081
Serum cholesterol 144 194.1±46.6 299 195.6±46.9 136 201.6±46.4 171 199.8±42.2 83 190.6±51 0.3601
(mg/dL)
Serum triglycerides 143 137.2±135.5 296 132.4±94.2 133 139.7±95.6 170 138.2±91.9 83 126.4±75.9 0.8561
(mg/dL)
HDL cholesterol (mg/dL) 129 41.8±13.3 257 41.4±14.8 116 42.4±13.7 144 38.8±12.7 76 42.9±15.6 0.1751
LDL cholesterol (mg/dL) 129 127.1±38.9 257 128.8±39 116 132.6±40.5 142 131±37 75 123.8±40.4 0.5571
VLDL cholesterol (mg/dL) 129 26±20.6 257 25.6±16.6 116 27.3±17.9 142 27.9±19 76 26.5±16 0.7671
Serum glucose (mg/dL)
<100 72 141 65 79 52
100-126 36 103 35 54 19 0.0162
>126 31 38 31 28 9
Serum creatinine (mg/dL) 141 1.3±0.6 293 1.2±0.4 136 1.2±0.4 169 1.3±0.3 82 1.2±0.3 0.0261
Serum uric acid (mg/dL) 90 8.1±2.2 184 8.1±2.5 79 7.9±2.3 91 8.1±2.9 50 8.6±2.6 0.6521
Data are reported as number of patients and means ± SD. Measurements were made anytime during the transplant evaluation.
Patients were followed for 905 + 846 days. P values in bold indicate statistically significant differences.1ANOVA and 2chi-square test
were used for statistical analysis.
myopathy group, the patients were older, they had a higher
body mass index, lower duration of symptoms, and lower
heart rate. In the group of patients with hypertensive car-
diomyopathy, we observed fewer males and deaths. There
was a significantly lower body mass index in patients with
Chagas’ cardiomyopathy compared with patients with heart
failure of other etiologies (P = 0.0003). The other variables
compared between Chagas’ and non-Chagas’ heart dis-
ease were not statistically different.
The highest mean values of serum HDL cholesterol,
LDL cholesterol and serum triglycerides were observed in
patients with hypertensive cardiomyopathy. The lowest
mean values of HDL cholesterol were observed in patients
with heart failure due to ischemic cardiomyopathy and the
lowest mean values of LDL cholesterol and serum triglyc-
erides were observed in patients with heart failure due to
all other etiologies. However, there were no statistical
differences between the etiologies. Serum glucose was
higher than 126 mg/dL in 137 patients (16.4%), and be-
tween 100 and 126 mg/dL in 247 patients (29.6%).
Subsequently, clinical variables and serum lipoprotein
variables were tested relative to mortality using a Cox
univariate model. The clinical variables associated with
mortality were diastolic blood pressure (P = 0.0082), se-
rum sodium (P < 0.0001), serum leukocyte count (P <
0.0001), serum creatinine (P < 0.0001), and serum uric
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acid (P < 0.0001) (Table 2). Lipid profile variables signifi-
cantly associated with mortality were serum cholesterol (P
< 0.0001), serum triglycerides (P = 0.045), HDL cholesterol
(P < 0. 0001), and LDL cholesterol (P = 0.0075) (Table 2).
Lipid profile variables, gender, age, and etiology were
submitted to multivariate analysis using a Cox proportional
hazards model. The associations that remained signifi-
cantly associated with mortality were HDL cholesterol (P =
Table 2. Univariate survival analysis.
Univariate analysis Number P Hazard 95%CI
of cases ratio
Duration of symptoms (days) 625 0.3100 1.00 (1.00-1.00)
Age (years) 829 0.0360 1.01 (1.00-1.02)
Body mass index (kg/m2) 449 0.6500 0.99 (0.96-1.02)
Systolic blood pressure (mmHg) 233 0.9500 1.00 (0.99-1.01)
Diastolic blood pressure (mmHg) 234 0.1600 0.99 (0.97-1.00)
Heart rate (bpm) 307 0.8100 1.00 (0.99-1.01)
Serum sodium (mEq/L) 791 <0.0001 0.92 (0.88-0.95)
Hemoglobin (g/dL) 807 0.8700 1.00 (0.94-1.08)
Hematocrit (%) 807 0.0510 1.02 (1.00-1.05)
Leukocytes (/mm3) 704 <0.0001 1.00 (1.00-1.00)
Platelets (1000/mm3) 616 0.7800 1.00 (0.99-1.00)
Serum cholesterol (mg/dL) 829 <0.0001 0.99 (0.99-0.99)
Serum triglycerides (mg/dL) 821 0.0450 0.99 (0.99-1.00)
HDL cholesterol (mg/dL) 719 <0.0001 0.97 (0.96-0.98)
LDL cholesterol (mg/dL) 716 0.0075 0.99 (0.99-0.99)
VLDL cholesterol (mg/dL) 717 0.0550 0.99 (0.98-1.00)
Serum glucose (mg/dL) 789 0.5700 1.00 (0.99-1.00)
Serum creatinine (mg/dL) 817 <0.0001 1.59 (1.32-1.92)
Serum uric acid (mg/dL) 490 0.0001 1.11 (1.05-1.18)
After exploratory analysis, clinical variables and serum lipoprotein variables
were analyzed using univariate Cox proportional hazards model.
0.0280), triglycerides (P < 0.0001), VLDL cholesterol (P =
0.0074), age (P = 0.0074), gender (P = 0.0040), and
idiopathic dilated cardiomyopathy relative to hypertensive
cardiomyopathy (P = 0.0085), which was the etiology
associated with the lowest mortality (Table 3).
For each 1 mg/dL increase of HDL cholesterol there was
a 1% decrease in mortality, and for each 1 mg/dL increase of
triglycerides there was a 4% decrease in mortality.
Discussion
Our data demonstrated that higher serum HDL
cholesterol and triglycerides were associated with
lower mortality in a cohort of outpatients with
symptomatic heart failure of different etiologies.
Previous reports in the literature with small
samples, a predominance of patients with is-
chemic etiologies of heart disease and different
statistical analysis of serum cholesterol and lipo-
proteins did not detect a significant relationship
between HDL cholesterol and survival rate of
patients with heart failure including Chagas’ heart
disease (3,4,6,7,17).
In fact, a protective role for HDL cholesterol in
patients with heart failure observed in our pa-
tients may be explained on the basis of the endo-
toxin-lipoprotein hypothesis, which suggests that
serum lipoproteins modulate inflammatory im-
mune function (6) and that HDL cholesterol has
antioxidant, anti-inflammatory and anti-thrombotic
properties (10,18).
The hypothesis that HDL cholesterol can be a
marker of coronary artery disease might influ-
ence our findings was evaluated by adjusting
etiologies and testing for interaction between co-
variates such as HDL cholesterol relative to is-
chemic heart disease. Higher mean serum HDL
cholesterol was observed in patients with hyper-
tensive cardiomyopathy and in patients with heart
failure grouped as other etiologies (valvular car-
diomyopathy, alcoholic cardiomyopathy, peripar-
tum cardiomyopathy, myocarditis, adriamycin tox-
icity, endomyocardial fibrosis, late postoperative
aortic dissection). The lowest mean serum HDL
cholesterol was detected in patients with heart
failure due to ischemic cardiomyopathy. First-
order interactions of etiology with the other
covariates including HDL cholesterol were tested
in the final model and revealed a non-significant
interaction at the 5% level of significance (P =
0.2512).
Table 3. Multivariate survival analysis.
Multivariate analysis Coefficient P Hazard 95%CI
(beta) ratio
Age (years) 0.0170 0.0074 1.02 (1.00-1.03)
Gender (female/male) 0.5727 0.0040 1.77 (1.20-2.62)
Chagas’ disease/hypertensive 0.3993 0.1200 1.49 (0.90-2.45)
Idiopathic/hypertensive 0.5950 0.0085 1.81 (1.16-2.82)
Ischemic/hypertensive 0.4292 0.0780 1.54 (0.95-2.48)
Others/hypertensive 0.2469 0.4000 1.28 (0.72-2.26)
Serum cholesterol (mg/dL) -0.0034 0.0930 0.99 (0.99-1.00)
Serum triglycerides (mg/dL) -0.0334 <0.0001 0.97 (0.95-0.98)
HDL cholesterol (mg/dL) -0.0043 0.0280 0.99 (0.99-1.00)
LDL cholesterol (mg/dL) -0.0003 0.9700 1.00 (0.98-1.02)
VLDL cholesterol (mg/dL) 0.0170 0.0074 1.01 (1.00-1.03)
Gender, age, and etiology were fitted and lipid profile variables were ana-
lyzed using multivariate Cox proportional hazards model.
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By contrast, in this study, serum cholesterol and LDL
cholesterol did not remain significantly associated with
mortality after multivariate analysis, as reported recently in
a study of 422 patients with heart failure due to idiopathic
dilated cardiomyopathy (17). The statistical treatment of
serum cholesterol and lipoproteins as continuous vari-
ables in the present study might be responsible for this
result. On the other hand, in previous experiences, serum
cholesterol and LDL cholesterol were evaluated in quintiles
(3), or serum cholesterol was evaluated in quartiles, or with
a cut-off value of 5.2 mmol/L (4) or in tertiles (17).
We also demonstrated a statistically significant rela-
tionship between serum triglycerides and mortality, as
previously reported (3,4,17). Further, we did not observe a
statistically significant association between body mass
index and mortality. This finding may be related to the fact
that few patients with cardiac cachexia were included in
the present study.
We have previously addressed the contribution of left
ventricle ejection fraction as evaluated by echocardiogra-
phy to prognosis (19). In the present study sample, we
were not able to demonstrate that ejection fraction, esti-
mated by echocardiography, predicts a less favorable
outcome. Serum sodium level in this study sample was a
significant prognostic factor in the univariate analyses, but
this significance was lost in multivariate analysis.
Our findings further support the concept of an increase
in HDL cholesterol as an additional therapeutic target for
patients with severe heart failure. Recently, drugs that
were meant to increase HDL cholesterol because of their
effects as inhibitors of cholesteryl ester transfer protein
(torcetrapib) have shown an increased risk of cardiovascu-
lar events (HR = 1.25; 95%CI = 1.09-1.44; P = 0.001) and
death from any cause (20,21).
Limitations of study
This study was performed at a large outpatient clinic of
a tertiary care university hospital. Thus, our observations
were not made under strict protocol conditions. We were
not able to control for specific drugs of medical therapy and
it is interesting to notice that our sample was a large one,
and our study was undertaken before routine statin thera-
py became more widely used in this clinical setting.
Thus, observations in this series may not be applicable
to other populations. Patients with heart failure of different
etiologies are also a limitation of the study.
In conclusion, we demonstrated that higher serum HDL
cholesterol and serum triglycerides were associated with
lower mortality in patients with heart failure of different
etiologies.
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